N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Quetiapine is an atypical antipsychotic drug that is also US FDA approved for treating bipolar depression, albeit by an unknown mechanism. To discover the potential mechanism for this apparently unique action, we screened quetiapine, its metabolite N-Desalkylquetiapine, and dibenzo[b,f][1,4]thiazepine-11(10-H)-one (DBTO) against a large panel of G-protein-coupled receptors, ion channels, and neurotransmitter transporters. DBTO was inactive at all tested molecular targets. N-Desalkylquetiapine had a high affinity (3.4 nM) for the histamine H(1) receptor and moderate affinities (10-100 nM) for the norepinephrine reuptake transporter (NET), the serotonin 5-HT(1A), 5-HT(1E), 5-HT(2A), 5-HT(2B), 5-HT(7) receptors, the alpha(1B)-adrenergic receptor, and the M(1), M(3), and M(5) muscarinic receptors. The compound had low affinities (100-1000 nM) for the 5-HT(1D), 5-HT(2C), 5-HT(3), 5-HT(5), 5-HT(6), alpha(1A), alpha(2A), alpha(2B), alpha(2C), H(2), M(2), M(4), and dopamine D(1), D(2), D(3), and D(4) receptors. N-Desalkylquetiapine potently inhibited human NE transporter with a K(i) of 12 nM, about 100-fold more potent than quetiapine itself. N-Desalkylquetiapine was also 10-fold more potent and more efficacious than quetiapine at the 5-HT(1A) receptor. N-Desalkylquetiapine was an antagonist at 5-HT(2A), 5-HT(2B), 5-HT(2C), alpha(1A), alpha(1D), alpha(2A), alpha(2C), H(1), M(1), M(3), and M(5) receptors. In the mouse tail suspension test, N-Desalkylquetiapine displayed potent antidepressant-like activity in VMAT2 heterozygous mice at doses as low as 0.1 mg/kg. These data strongly suggest that the antidepressant activity of quetiapine is mediated, at least in part, by its metabolite N-Desalkylquetiapine through NET inhibition and partial 5-HT(1A) agonism. Possible contributions of this metabolite to the side effects of quetiapine are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“Quetiapine is a histamine H1 receptor antagonist with a Ki of 11 nM, which induces weight gain (Allison et al, 1999) and has pronounced sedative effects (Cohrs et al, 2004; Thase et al, 2006).”
BackgroundCryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationRothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
Self-citationEffectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 1×
“Recent observations indicate that the Neuropsychopharmacology use of adjunctive, standard antidepressant medication in the treatment of bipolar depression, as compared with the use of mood stabilizers, such as lithium or valproate alone, does not increase antidepressant efficacy (Sachs et al, 2007).”
BackgroundTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 2×
“Our results imply that the antidepressant effects of quetiapine in bipolar depression (Calabrese et al, 2005; Thase et al, 2006) are mediated, at least in part, by the potent antidepressant activity of N-Desalkylquetiapine.”
BackgroundResultKroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Self-citationSerotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722 · cited 3×
“For example, drug-induced valvular heart disease is frequently due to the 5-HT2B receptor agonism of metabolites (Roth, 2007; Rothman et al, 2000), while the M1 muscarinic receptor activation by the metabolite desmethylclozapine may contribute to the clinical efficacy of the antipsychotic drug…”
BackgroundSelf-citation
Cited by
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Self-citationNelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“A feature of quetiapine’s pharmacology which might explain its better antidepressant response than that of other atypicals is the noradrenaline reuptake inhibiting properties of its major metabolite norquetiapine (Jensen et al. 2008).”
BackgroundLigand discovery from a dopamine D3 receptor homology model and crystal structure
Carlsson, J., Coleman, R. G., Setola, V., Irwin, J. J., Fan, H., Schlessinger, A., Sali, A., Roth, B. L., & Shoichet, B. K. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.662 · Cited by 308
Self-citationSelectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
Self-citationQuetiapine for acute bipolar depression: a systematic review and meta-analysis
Suttajit, S., Srisurapanont, M., Maneeton, N., & Maneeton, B. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s63779 · Cited by 255
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Ignácio, Z. M., Réus, G. Z., Abelaira, H. M., Maciel, A. L., de Moura, A. B., Matos, D., Demo, J. P., da Silva, J. B. I., Gava, F. F., Valvassori, S. S., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.044 · Cited by 53
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51
McIntyre, A., Paisley, D., Kouassi, E., & Gendron, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38228 · Cited by 43
“The analgesic effects of quetiapine XR may be mediated in part by its dopaminergic actions as well as its effects on both the serotonergic and noradrenergic systems (24,25,30).”
BackgroundInfluentialEffects of quetiapine on DNA methylation in neuroblastoma cells
Sugawara, H., Bundo, M., Asai, T., Sunaga, F., Ueda, J., Ishigooka, J., Kasai, K., Kato, T., & Iwamoto, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.010 · Cited by 32
Rational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia
Hattori, S., Kishida, I., Suda, A., Miyauchi, M., Shiraishi, Y., Fujibayashi, M., Tsujita, N., Ishii, C., Ishii, N., Moritani, T., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.004 · Cited by 29
Kozikowski, A. P., Cho, S. J., Jensen, N. H., Allen, J. A., Svennebring, A. M., & Roth, B. L. (2010) · ChemMedChem · doi:10.1002/cmdc.201000186 · Cited by 28
Self-citation
Metadata
- Authors
- Jensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L.
- Venue
- Neuropsychopharmacology
- Published
- 2007-12-05
- Volume
- 33
- Issue
- 10
- Pages
- 2303-2312
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074852398
- Cited by
- 316
- References
- 42
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.